GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Price-to-Operating-Cash-Flow

BCRX (BioCryst Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Dec. 13, 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-12-13), BioCryst Pharmaceuticals's share price is $7.60. BioCryst Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.27. Hence, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

BCRX's Price-to-Operating-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 26.38
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

BioCryst Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Sep. 2024 was $0.04. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.27.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 15.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 7.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -6.50% per year.

During the past 13 years, BioCryst Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 39.20% per year. The lowest was -70.80% per year. And the median was 4.00% per year.


BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCryst Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.



BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=7.60/-0.272
=

BioCryst Pharmaceuticals's Share Price of today is $7.60.
BioCryst Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.27.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

BioCryst Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin director ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244